Procedures for the GMP-Compliant Production and Quality Control of [ 18 F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer Oliver C. Neels 1,* , René Martin 2 , Jens Cardinale 3 , René Smits 2 , Martin Schäfer 1 , Alexander Hoepping 2 , Marco Müller 2 , Klaus Kopka 1 1 German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg; 2 ABX advanced biochemical compounds, Heinrich-Glaeser-Strasse 10-16, 01454 Radeberg; 3 Ludwig Boltzmann Institute Applied Diagnostics, Waehringer Guertel 18-20 1090 Vienna. 1 * Corresponding author: o.neels@dkfz.de
Abstract: Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important radiopharmaceuticals for the PET-imaging of prostate cancer. In this connection, we recently developed the fluorine-18-labelled PSMA-ligand [ 18 F]PSMA-1007 as the next generation radiofluorinated Glu-ureido PSMA inhibitor after [ 18 F]DCFPyL and [18F]DCFBC. Since radiosynthesis so far has been suffering from rather poor yields, novel procedures for the automated radiosyntheses of [ 18 F]PSMA-1007 have been developed. We herein report on both the two-step and the novel one-step procedures, which have been performed on different commonly-used radiosynthesisers. Using the novel one-step procedure, the [ 18 F]PSMA-1007 was produced in good radiochemical yields ranging from 25 to 80% and synthesis times of less than 55 min. Furthermore, upscaling to product activities up to 50 GBq per batch was successfully conducted. All batches passed quality control according to European Pharmacopoeia standards. Therefore, we were able to disclose a new, simple and, at the same time, high yielding production pathway for the next generation PSMA radioligand [ 18 F]PSMA-1007. Actually, it turned out that the radiosynthesis is as easily realised as the well- known [ 18 F]FDG synthesis and, thus, transferable to all currently-available radiosynthesisers. Using the new procedures, the clinical daily routine can be sustainably supported in-house even in larger hospitals by a single production batch. Keywords: PSMA; fluorine-18; PET; GMP; automation 2
Transformation of PSMA-617 into PSMA-1007 PSMA-617 PSMA-1007 Radiolabel-bearing Moiety [ 177 Lu]PSMA-617 [ 18 F]PSMA-1007 GM 24 h p.i. MIP 1 h p.i. Functional Spacer Pharmacophore Giesel et al. , Eur J Nucl Med Mol Imaging 2016, 43 (10), 1929-1930. 3
[ 18 F]PSMA-1007: From two-step to single-step synthesis Olberg et al. , J Med Chem 2010, 53 (4), 1732 – 1740. Cardinale et al. , J Nucl Med 2017, 58 (3),425-432. Cardinale et al. , Pharmaceuticals (Basel) 2017, 10 (4), pii: E77. 4
Automation on a NI FDG / GE Tracerlab FX FN module Azeotropic drying Addition of 1.6 mg F-18 eluted with 750 F-18 trapped on with 1 mL ACN PSMA-1007 µL TBAHCO 3 QMA precursor in 2 mL solution into reactor DMSO and subsequent heating at 85°C for 10 minutes 5
Automation on a NI FDG / GE Tracerlab FX FN module Transfer of crude Rinsing of reactor mixture onto SPE with 23 mL 5% EtOH cartridge combination with 10 mL 5% EtOH 6
Automation on a NI FDG / GE Tracerlab FX FN module Elution of sideproducts with 3 mL 30% EtOH 7
Automation on a NI FDG / GE Tracerlab FX FN module Elution of [ 18 F]PSMA-1007 with 4 mL 30% EtOH into collection vial holding 11 mL 0.9% saline and 100 mg sodium ascorbate 8
[ 18 F]PSMA-1007: Specification Active ingredients 100 – 2000 MBq [ 18 F]PSMA-1007/mL Other ingredients Sodium ascorbate Solution 0,9 % NaCl ≥ 90 Vol% Ethanol ≤ 10 Vol% V max * 10 mL Specification Appearance Clear and colorless pH 4.5 – 7.5 [ 18 F]PSMA-1007: Radiochemical ≥ 95 % (HPLC/TLC) purity [ 18 F]Fluoride and other radiochemical impurities: ≤ 5 % (HPLC/TLC ) Chemical purity Acetone: ≤ 50 mg/V max Acetonitrile: ≤ 4.1 mg/V max DMSO: ≤ 50 mg/V max TBA: ≤ 2.6 mg/V max PSMA-1007: ≤ 0.1 mg/ V max Any single unspecific impurity (with reference to PSMA- ≤ 0.1 mg/ V max 1007 solution): The sum of PSMA-1007 and all unspecific impurities (with ≤ 0.5 mg/V max reference to PSMA-1007 solution): Disregard limit (with reference to PSMA-1007 solution): ≤ 0.3 of 0.1 mg/V max Identity 18 F corresponding to a peak at 511 keV Radionuclidic ≥ 99,9 % purity Approximate half-life 110 ± 5 min Sterility Sterile Endotoxins ≤ 175 I.E./V max Shelf-life 8 hours Cardinale et al. , Pharmaceuticals (Basel) 2017, 10 (4), pii: E77. *V max being the maximum injectable volume per patient 9
[ 18 F]PSMA-1007: Radiosynthesis results NI FDG / GE GE Tracerlab MX / IBA Synthera+ Tracerlab FX FN ORA Neptis Mosaic- RS N= 16 10 10 Amount of Precursor 1.6 mg 1.6 mg 1.0 mg used Radiochemical Yields 24.3 - 82.4 % 43.3 - 52.8 % 59.5 - 72.8 % (n.d.c.) Synthesis Time 55 min 45 min 35 min Quality Control All results within specification Cardinale et al. , Pharmaceuticals (Basel) 2017, 10 (4), pii: E77. 10
[ 18 F]PSMA-1007: Improvement of Quality PSMA-1007: 8.2 µg/mL 11
[ 18 F]PSMA-1007: Improvement of Quality Acetate PSMA-1007: 2.7 µg/mL 12
Conclusion and outlook • GMP-compliant radiosynthesis of [ 18 F]PSMA-1007 using SPE purification on a range of commercially available radiosynthesizers in very good radiochemical yields and (improved) quality • [ 18 F]PSMA-1007 has arrived in the clinic rapidly and can be used in combination with 177 Lu/ 225 Ac-PSMA-617 in theragnostic applications • A global academic initiative will start soon to assess the clinical value of [ 18 F]PSMA- 1007 (www.psma-imaging.org) • Remaining challenges: identify the (radio)chemical impurities and investigate the mechanism of radiofluorination of unprotected precursor 13
Acknowledgements Division of Radiopharmaceutical Chemistry Radiochemistry and R&D, Medicinal Chemistry Clinical Cooperation Unit Nuclear Medicine Our national and international collaborators 14
Recommend
More recommend
